Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration

Author(s):  Pereboom Marieke, Becker Matthijs L, Amenchar Mostapha, Verweij Sjoerd L, van der Hoeven Ruud TM, Mulder Inge J

Issue:  Jan/Feb 2015 - Volume 19, Number 1
View All Articles in Issue

Page(s):  70-72

Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration Page 1
Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration Page 2
Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration Page 3

Download in electronic PDF format for $75

Abstract:  Intravitreal bevacizumab is frequently used off-label for the treatment of neovascular age-related macular degeneration, but there are concerns about the safety of intravitreal administered bevacizumab. It is suggested that repackaging bevacizumab in plastic syringes could affect the safety due to the unknown shelf life of the syringes. In this study, we analyzed the shelf life of the repackaged bevacizumab syringes, stored at 4°C, at certain time intervals. Over the 32 days tested, bevacizumab concentration and the pH were stable. However, the number of particles in the repackaged bevacizumab syringes increased during storage at 4°C and had exceeded the limits for intravitreal injections after 7 days. Since the number of particles seems to be the limitation of the shelf life of repackaged bevacizumab, it is necessary to quantify the number of particles in repackaged bevacizumab. Based on our results the maximum shelf life of repackaged bevacizumab should be 3 days.

Related Keywords: peer reviewed, bevacizumab, monoclonal antibody, intravitreal administration, neovascular age-related macular degeneration, eye diseases, ophthalmic disorders, plastic syringes, repackaging, shelf life, vascular endothelial growth factor antagonist, VEGF inhibitor, stability, particles, particulate contamination

Related Categories: OPHTHALMICS, PACKAGING, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration
Pereboom Marieke
, Becker Matthijs L, Amenchar Mostapha, Verweij Sjoerd L, van der Hoeven Ruud TM, Mulder Inge J
Jan/Feb 2015
Pg. 70-72

Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration
Dib Jean G
, Abdulmohsin Saud
Jan/Feb 2008
Pg. 8-14

Five Compounds for Treating Diabetes-Related Conditions
Meece Jerry
May/Jun 2003
Pg. 170-174

Physicochemical and Microbiological Stability of Vancomycin 10-mg/mL Intravitreal Syringes
Bartoll Aaron Puplà
, Bellés Medall Maria Dolores, Peñarrocha Josep Edo, Escrig Laura Solaz, Clemente Ruben Eguren, Azuara Julia Bodega, Piqueres Raul Ferrando
Jul/Aug 2022
Pg. 330-335

Treating Inner Ear Disorders with Intratympanic Drug Administration
McElhiney Linda F
Jul/Aug 2011
Pg. 302-307

Infliximab 1% Ophthalmic Solution
Allen Loyd V Jr
Jan/Feb 2017
Pg. 62

I See Colors: Using Vital Dyes in Diagnosing Ophthalmic Disease
McElhiney Linda F
May/Jun 2012
Pg. 190-195

Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation
Robert Marie-Claude
, Spurr-Michaud Sandra, Frenette Mathieu, Young David, Gipson Ilene K, Dohlman Claes H
Sep/Oct 2014
Pg. 418-426

Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Chemical Stability of Admixtures Combining Ziconotide with Fentanyl or Sufentanil During Simulated Intrathecal Administration
Shields David E
, Aclan Jennifer, Szatkowski Aaron
Sep/Oct 2008
Pg. 463-466

Treating Canine Hepatic Disease
Davidson Gigi S
May/Jun 2003
Pg. 188-191

Basics of Sterile Compounding: Ophthalmic Preparations, Part 2: Suspensions and Ointments
Allen Loyd V Jr
Nov/Dec 2016
Pg. 495-500

Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis
Mixon William
, Angelle Patricea (Patsy), Chang Richard I
Nov/Dec 2009
Pg. 506-515

Long-term Stability of Epitheliotropic Factors in Frozen Serum Eye Drops
Sahyoun Jean-Yves
, Cloutier Marc, Frenette Mathieu, Robert Marie-Claude
Jul/Aug 2022
Pg. 336-341

Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions
Allen Loyd V Jr
Sep/Oct 2016
Pg. 399-404

Stability of Furosemide 5 mg/mL in Polypropylene Syringes
van der Schaar JAJ
, Grouls R, Franssen EJF, Crul M
Sep/Oct 2019
Pg. 414-417

Treatment Options for Male Hypogonadism
Biundo Bruce
Jan/Feb 2013
Pg. 28-38

Jet Injection Devices for the Needle-free Administration of Compounds, Vaccines, and Other Agents
Logomasini Mark A
, Stout Richard R, Ron Marcinkoski
Jul/Aug 2013
Pg. 270-280

Treatment Options for Male Hypogonadism
Biundo Bruce
Jan/Feb 2024
Pg. 6-14

Return to Top